Watanabe, Junichiro
Ito, Yoshinori
Ohsumi, Shozo
Mizutani, Mitsuhiro
Tashiro, Hideya
Sakurai, Kenichi
Takahashi, Masato
Saito, Tsuyoshi
Tsurutani, Junji
Mukai, Hirofumi
Yoshinami, Tetsuhiro
Takao, Shintaro
Yamamoto, Yasuhisa
Matsuoka, Toshiyuki
Iwase, Hirotaka
Iwata, Hiroji
Nakamura, Seigo
Saeki, Toshiaki
Funding for this research was provided by:
Eisai Co., Ltd.
Article History
Received: 14 April 2017
Accepted: 20 June 2017
First Online: 29 June 2017
Compliance with ethical standards
:
: J. Watanabe is a medical advisor for Eisai Co., Ltd. and Astra Zeneca K.K. and has received honorarium from Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Chugai Pharmaceutical Co., Ltd. Y. Ito received scholarship grants from Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., PAREXEL International Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., EPS Corporation, Daiichi Sankyo Co., Ltd., MSD K.K., Sanofi K.K., Eli Lilly Japan K.K., and AstraZeneca K.K. M. Takahashi received honoraria for lectures from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Eisai Co., Ltd. T. Matsuoka is an employee of Eisai Co., Ltd. H. Iwata received honorarium from Eisai Co., Ltd. S. Nakamura is a medical advisor for Eisai Co., Ltd. (Tokyo, Japan). T. Saeki is a medical advisor for and received honorarium from Eisai Co., Ltd. All other authors have no conflicts of interest to declare.
: The study was conducted in accordance with the Declaration of Helsinki and Japanese regulatory requirements stipulated in the GPSP. Approval from the institutional ethics committee/institutional review board was obtained prior to commencement of the study.
: For this type of study formal consent was not required.